Does Ozempic Cause Muscle Loss? What Women Over 40 Should Know

GLP-1 treatment can reduce lean mass as weight falls, but lean mass is not the same measurement as skeletal muscle or strength. In the SURMOUNT-1 tirzepatide substudy, roughly three quarters of weight lost was fat and one quarter lean mass³. That average is not a prediction that every woman will lose a quarter of her weight from muscle.

The part the general advice misses

Every article about lean mass on a GLP-1 tells you the same two things: some share of what you lose is not fat, and you should eat protein and lift. Both are true. Neither is the part that matters most if you are in your forties or fifties.

The menopause transition moves body composition on its own — toward more fat and less lean mass — independently of anything you take¹. So a woman starting a GLP-1 in midlife is not adding lean-mass loss to a stable baseline. She is adding it to one that is already sloping down. Same medication, same percentage, different consequence. That is the whole argument of this page, and it is why the generic advice under-serves exactly the readers most likely to need it.

This is general education rather than medical advice, and body composition is worth discussing with a clinician who can see your history.

What the Ozempic, Wegovy and Zepbound studies measured

When weight comes off, some of it is fat-free mass — that is true of dieting, surgery and medication alike, and it is not unique to GLP-1s². The useful question is how much, and under what conditions.

Body composition was measured directly in a substudy of SURMOUNT-1, the tirzepatide obesity trial: fat mass fell proportionally more than lean mass, so the ratio of the body that is lean improved even as the absolute lean figure came down³. A 2026 study of semaglutide looked at fat mass, lean mass and muscle function together — function being the thing a scan does not tell you⁴.

In the semaglutide study, grip strength rose by an average of 4.5 kg over the year, and the share of people with sarcopenic obesity (low muscle alongside obesity) fell from 49% to 33%⁴. These findings concern the studied populations and doses. They do not establish the same change for someone taking a different semaglutide product, following a different eating pattern or living with another condition.

Two honest caveats worth holding: a smaller body genuinely needs less muscle to carry it, so some of the loss is appropriate rather than harmful, and losing lean mass is not the same as losing strength.

A scan and a strength assessment answer different questions

The SURMOUNT-1 result comes from 160 participants with usable baseline and follow-up DXA scans, not a direct measurement of muscle loss in every person enrolled in the larger trial. Participants were 73% women. The approximate fat-versus-lean proportion was also similar in the placebo group³. That matters when interpreting a headline claiming the medicine uniquely destroys muscle.

DXA-derived lean tissue is not a muscle-only compartment. A primary comparison of body-composition methods found that DXA lean estimates and a muscle-specific creatine method differed, despite being correlated⁸. A falling lean-mass number therefore cannot identify the exact amount of skeletal muscle lost or establish impaired function on its own.

Ask what the clinic measures and what change would trigger an assessment. A scan can add information, but so can a clinically appropriate assessment of strength, mobility and food intake. New difficulty rising from a chair, carrying usual groceries or completing familiar activity deserves discussion rather than reassurance based only on a better lean-to-fat ratio.

Why the pace of weight loss deserves review

The pace and nutritional context of weight loss deserve attention alongside the medicine itself.

The TEMPO trial randomized postmenopausal women with obesity to severe versus moderate energy restriction and measured lean mass and body composition⁵. It was a diet trial, not a comparison of GLP-1 doses or a test of a medication-titration strategy. It supports taking the intensity of weight reduction seriously, while leaving questions about the best approach during drug treatment.

Tell the prescriber if appetite suppression makes adequate meals difficult or weight is falling more quickly than expected. Ask whether the nutrition, activity and medication plan needs review. Do not change the dose to meet an internet weight-loss target.

Protein and resistance work, with the women-specific caveats

Protein matters, and the honest framing is that it matters more when total intake falls, because the same relative shortfall now sits inside a much smaller amount of food. In postmenopausal women specifically, a meta-analysis of whey protein supplementation found effects on body composition — modest, and clearly conditional on resistance exercise rather than a substitute for it⁶.

Resistance training is the intervention nobody disputes. What is newer is that creatine monohydrate now has a postmenopausal-specific systematic review behind it, covering lean mass, strength and bone density⁷ — bone being the outcome that makes this more than cosmetic in midlife, since the same transition is thinning it, and a randomized GLP-1 trial has now found measurably lower bone density at one year in adults already at elevated fracture risk — see our dedicated guide to GLP-1 and bone density for what that trial found and what it does and doesn't mean.

Note what all of this shares: it is about what you add, not about which molecule you were prescribed. Switching medicines is not a lean-mass strategy.

What to actually ask a provider

• What rate of loss are we aiming for, and what would make us slow it down? A program with no answer is not monitoring composition.
• What is being tracked besides the scale? Weight alone cannot distinguish a good month from a bad one here.
• What happens in year two? Midlife weight is a long problem. A program built for a twelve-week sprint is answering a different question.
• Who coordinates with whoever manages my hormone therapy or bone health?

A provider that runs labs and adjusts has levers; one whose only lever is the next dose does not. Our labs and monitoring guide covers what a real panel includes, the perimenopause and menopause guide covers the wider transition, and our menopause provider ranking scores every program on oversight, hormonal fit and ongoing support. If hair is also thinning, that has its own differential — see what is actually causing the shedding. For everything else to raise with a provider, see our hub on GLP-1 side effects in women.

If a trip will interrupt meals, activity or access to the clinic, plan ahead with our GLP-1 travel guide. If treatment has already been interrupted, discuss restarting after missed doses with the prescriber rather than resuming an old dose from memory.

If cost or side effects make you consider ending treatment, discuss what happens after stopping a GLP-1, including how to follow weight, food intake and strength during the transition.

If your legs and hips hold fat that dieting never moves, that may be lipedema, which needs different treatment. And if a clinic pitches testosterone to protect muscle, read what testosterone does and doesn't do for women first.